Qiagen saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 69 to 73.
IBD's proprietary rating measures share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating north of 80 as they launch their biggest runs. See if Qiagen can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
Qiagen is trading within a buying range after breaking past a 47.44 buy point in a flat base. Once a stock moves 5% or higher beyond the original entry, it's considered out of buy range.
In terms of fundamentals, Qiagen has posted rising EPS growth over the last two quarters. Top line growth has also risen during the same period. The company is expected to report its next quarterly numbers on or around Feb. 5.
Qiagen holds the No. 17 rank among its peers in the Medical-Products industry group. Boston Scientific, Globus Medical and ResMed are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
